Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Université de Montréal
$105,000.00
Characterization of a negative feedback loop induced by mTORC1 to regulate mTORC2 activity.
FY 2008-09
Summary
Human cells integrate extracellular signals to decide when to proliferate. When pro-proliferative signals are captured, the cell triggers an intracellular response. This signal transduction is often mediated by protein kinases that phosphorylate substrates, which drive cells to divide. When these mechanisms are not correctly regulated, as in cancerous cells that have acquired oncogenic mutations, cells often over proliferate resulting in cancer development.
The protein kinase mTOR is crucial for cellular proliferation because it integrates signals from growth factors to drive cells into division. Inappropriate regulation of mTOR plays an important role in many types of cancer. In human cells, mTOR forms two distinct complexes, the mTOR complex 1 and 2 (mTORC1 and 2). mTORC1 is the target of rapamycin, a chemotherapeutic drug currently in clinical trials for anti-cancer treatments. This complex regulates the synthesis of proteins, an essential step for proper cell proliferation. The second complex mTORC2 is crucial for the activation of Akt, a protein kinase often over-activated in cancer cells. Preliminary data indicate that mTORC1 negatively regulate mTORC2 activity. This finding is worth pursuing in detail because chemotherapeutic agents targeting mTORC1 may result in enhanced mTORC2 and Akt oncogenic activity, thereby attenuating their therapeutic potential. The research project part of this application will consist of characterizing the molecular mechanisms involved in mTORC2 regulation by mTORC1 using various molecular and cell biological approaches. A better understanding of the regulation of mTORC1 and mTORC2 is essential and may help in the design of improved anti-cancer drugs for the eventual treatment of patients worldwide.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
184388
Name
Julien Louis-André
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterization of a negative feedback loop induced by mTORC1 to regulate mTORC2 activity.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cancer; Cell Culture; Cell Signalling; Cellular Growth And Proliferation; Immunoblotting; Immunoprecipitations; Oncogene; Phosphorylation; Protein Kinases; Proteomics
Abstract
Human cells integrate extracellular signals to decide when to proliferate. When pro-proliferative signals are captured, the cell triggers an intracellular response. This signal transduction is often mediated by protein kinases that phosphorylate substrates, which drive cells to divide. When these mechanisms are not correctly regulated, as in cancerous cells that have acquired oncogenic mutations, cells often over proliferate resulting in cancer development.
The protein kinase mTOR is crucial for cellular proliferation because it integrates signals from growth factors to drive cells into division. Inappropriate regulation of mTOR plays an important role in many types of cancer. In human cells, mTOR forms two distinct complexes, the mTOR complex 1 and 2 (mTORC1 and 2). mTORC1 is the target of rapamycin, a chemotherapeutic drug currently in clinical trials for anti-cancer treatments. This complex regulates the synthesis of proteins, an essential step for proper cell proliferation. The second complex mTORC2 is crucial for the activation of Akt, a protein kinase often over-activated in cancer cells. Preliminary data indicate that mTORC1 negatively regulate mTORC2 activity. This finding is worth pursuing in detail because chemotherapeutic agents targeting mTORC1 may result in enhanced mTORC2 and Akt oncogenic activity, thereby attenuating their therapeutic potential. The research project part of this application will consist of characterizing the molecular mechanisms involved in mTORC2 regulation by mTORC1 using various molecular and cell biological approaches. A better understanding of the regulation of mTORC1 and mTORC2 is essential and may help in the design of improved anti-cancer drugs for the eventual treatment of patients worldwide.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Julien, Louis-André
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~